NYSE$MED

Medifast Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Medifast's financial performance in Q1 2024 was marked by a decrease in revenue and active coaches, alongside strategic investments in future growth initiatives.

Medifast reported a decrease in revenue to $174.7 million, driven by a decline in active OPTAVIA Coaches and lower coach productivity. Net income was $8.3 million, with EPS at $0.76. The company is focusing on transforming its OPTAVIA offer to include support for consumers using medical weight loss solutions and investing in company-led customer acquisition initiatives.

  • Revenue decreased by 49.9% to $174.7 million compared to Q1 2023.
  • The number of active earning OPTAVIA Coaches decreased by 35.6% to 37,800.
  • Net income was reported at $8.3 million, or $0.76 per diluted share.
  • The company is investing in medically supported weight loss activities and company-led acquisition initiatives.

Headline financials

Total Revenue

$175M

Previous: $349M-49.9%
EPS (adj)

$0.66

Previous: $3.67-82.0%
Capital Expenditures

-$1.84M

Previous: -$2.12M+13.0%
Free Cash Flow

$6.48M

Previous: $37.9M-82.9%
Net Income

$8.32M

Previous: $40M-79.2%
Operating Income

$7.94M

Previous: $53.5M-85.2%
Gross Profit

$127M

Previous: $246M-48.3%
R&D Expense

$1M

No prior period
Stock-Based Comp

$2.17M

Previous: $606K+258.3%

Revenue & EPS history

Medifast · Revenue · Quarterly

$175M

Q1 2024-49.9%vs Q1 2023
Beat estimate in 14 of 15 quarters(93%)
ActualEstimate

Forward guidance

The company expects second quarter 2024 revenue to be in the range of $150 million to $170 million and second quarter 2024 diluted EPS to be in the range of $0.05 to $0.40. The EPS range excludes the costs related to the initiation of the LifeMD collaboration and any gains or losses from changes in the market price of the company’s LifeMD common stock investment.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+0.4%

Avg return

30 days after

51%

33 / 65 earnings

Positive

+31.6%

Q4 2017

Best reaction

-29.9%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.2%+19.7%+16.7%
Q4 2025-0.8%-1.9%-7.4%
Q3 2025+0.8%+0.4%-8.6%
Q1 2025-0.6%+5.3%+10.8%
Q4 2024-11.4%-8.4%-11.1%
Q3 2024+9.8%+3.1%+6.2%
Q2 2024-5.6%-9.0%-11.8%
Q1 2024-18.3%-20.8%-25.4%
Q4 2023-19.2%-18.5%-28.7%
Q3 2023-1.5%-6.5%+3.3%
Q2 2023-9.5%-4.9%-18.5%
Q1 2023-3.8%-0.7%-14.1%
Q4 2022-10.8%-4.6%-15.3%
Q3 2022-3.2%-1.6%+9.0%
Q2 2022-15.2%-21.9%-31.9%
Q1 2022+5.4%+1.8%-2.0%
Q4 2021-5.6%+1.7%-6.4%
Q3 2021+3.7%+4.7%-7.1%
Q2 2021-8.7%-14.1%-17.4%
Q1 2021+7.8%+18.9%+35.3%
Q4 2020-3.9%-0.8%-14.7%
Q3 2020+12.9%+23.5%+45.4%
Q2 2020-5.7%-5.0%-8.0%
Q1 2020+18.5%+30.1%+46.7%
Q4 2019-9.7%-13.4%-31.5%
Q3 2019-29.9%-24.8%-14.7%
Q2 2019-7.6%-7.8%-10.5%
Q1 2019-2.1%+3.6%-12.1%
Q4 2018+0.9%-0.7%+0.3%
Q3 2018-28.3%-25.3%-32.4%
Q2 2018+25.8%+17.4%+35.0%
Q1 2018+22.3%+19.3%+50.0%
Q4 2017+31.6%+32.5%+44.0%
Q3 2017+14.7%+13.1%+16.6%
Q2 2017+18.6%+20.7%+31.7%
Q1 2017+3.4%+3.8%-6.1%
Q4 2016-3.7%-4.4%-1.4%
Q3 2016-5.0%-4.5%-4.7%
Q2 2016-0.2%+0.8%+5.9%
Q1 2016+0.8%
Q4 2015-5.6%
Q3 2015+6.9%
Q2 2015-9.2%
Q1 2015+5.3%
Q4 2014-3.1%
Q3 2014+2.5%
Q2 2014-9.5%
Q1 2014-8.5%
Q4 2013+3.4%
Q3 2013+0.5%
Q2 2013-4.3%
Q1 2013-3.8%
Q4 2012-5.4%
Q3 2012+10.4%
Q2 2012+28.5%
Q1 2011+8.9%
Q1 2012+3.2%
Q4 2011+0.9%
Q4 2009+0.9%
Q3 2010+1.9%
Q3 2011+1.9%
Q4 2010+4.3%
Q2 2010+4.3%
Q2 2011+4.3%
Q1 2010+10.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro